Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 11 of the 21 sources its claims cite were checked for support.
Abstract
Objectives: This study tested the acceptability and efficacy of an Acceptance and Commitment Therapy and compassion-based intervention (LIFEwithIBD) in people with IBD through a two-arm RCT. Methods: Participants were recruited at the Gastroenterology Department of the Coimbra University Hospital between June and September 2019. Of the 355 patients screened, those who accepted to participate were randomly assigned to one of two conditions: experimental group (LIFEwithIBD; n = 25) or control group (waitlist; n = 29). Participants completed self-report measures at baseline (T0), post-intervention (T1), and 3-month (T2) and 12-month (T3) follow-ups. Intervention acceptability was assessed. Efficacy was examined using intent-to-treat ANCOVA at post-intervention after adjusting for baseline values of depressive, anxiety, and stress symptoms (primary outcomes). Linear mixed models for all longitudinal outcomes were also analysed. Inflammatory and disease biomarkers were determined at T0 and T3. Results: Acceptability results revealed a high level of satisfaction and perceived usefulness regarding the intervention. Both groups experienced a significant decrease in stress symptoms and IBD symptom perception at T1. No significant differences were observed at follow-up for the primary outcomes. The experimental group reported significantly lower Crohn’s disease Symptom severity at T2 than the control group. Post-hoc analyses designed to mitigate floor effects revealed substantial treatment effects for the experimental group regarding anxiety symptoms. No significant differences were observed in clinical biomarkers from T0 to T3. Conclusion: The LIFEwithIBD intervention shows promising, although preliminary, benefits for managing disease activity and reducing anxiety symptoms in IBD patients with high severity of psychological distress. Clinical trial registration: https://www.clinicaltrials.gov/ct2/show/NCT03840707, identifier NCT03840707. Copyright © 2024 Ferreira, Pereira, Skvarc, Oliveira, Galhardo, Ferreira, Lucena-Santos, Carvalho, Matos-Pina, Rocha, Portela and Trindade.
Overview
CoChat Summary
## TL;DR
This two-arm randomized controlled trial tested the acceptability and preliminary efficacy of the LIFEwithIBD ACT- and compassion-based group intervention in people with inflammatory bowel disease (IBD). The intervention was well accepted, but it did not improve the primary distress outcomes versus control at follow-up, with limited signals for anxiety and Crohn’s disease symptom severity.
## Key findings
- Of 355 patients screened, 76 were randomized: 38 to LIFEwithIBD + TAU and 38 to TAU; 23 later self-excluded before the intervention began, leaving 25 in the experimental group and 29 in the control group in the abstracted analysis.
- Acceptability was high: “all participants” said the intervention was worthwhile and would recommend it to another person with IBD; most considered it high quality and useful.
- No significant between-group differences were found at post-treatment on the primary outcomes (DASS-21 depression, anxiety, stress) after adjusting for baseline scores, and no significant differences were seen at follow-up for the primary outcomes.
- Secondary findings were limited: the experimental group had significantly lower Crohn’s disease symptom severity at 3 months (T2) than control (ηp² = 0.155, p = 0.042), and exploratory analysis found a significant post-treatment anxiety difference (F(1,13) = 7.56, p = 0.017, ηp² = 0.368). No significant biomarker differences were observed from T0 to T3, except albumin increased in the control group (p = 0.004) and showed a nonsignificant trend in the experimental group (p = 0.066).
## Methods
- Two-arm RCT recruiting adults with IBD from the Gastroenterology Department of Coimbra University Hospital between June and September 2019; inclusion required age 18–65, Portuguese literacy, IBD diagnosis for at least 6 months, and informed consent.
- Randomized conditions: LIFEwithIBD + treatment as usual versus waitlist/treatment as usual; participants completed self-report measures at baseline (T0), post-intervention (T1), 3 months (T2), and 12 months (T3), with biomarkers measured at T0 and T3.
- Main analyses used intent-to-treat ANCOVA for post-intervention outcomes adjusting for baseline values, linear mixed models for longitudinal outcomes, and two-way ANOVA/Sidak tests for biomarkers; acceptability was assessed via post-intervention questionnaire.
## Limitations
- The paper explicitly states a relatively small sample size and a considerable attrition rate.
- The authors state that participants in both groups had low baseline psychological distress, which may have reduced sensitivity to change; they suggest future studies include patients with higher distress.
- The paper explicitly notes reliance on self-report questionnaires and baseline differences in self-critical attitude and psychological flexibility between groups.
- Evident from the text: some post-hoc analyses were exploratory with no correction for multiple comparisons, and COVID-19 lockdown periods coincided with later assessments, which could have affected results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 3 Not checked · 37 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No significant differences were observed at follow-up for the primary outcomes.”
- Also stated in: § Efficacy assessment · plain
“We observed no significant differences between groups at T1 on any of the DASS sub-scales after adjusting for T0 symptom scores.”
§ Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Efficacy assessment · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Post-hoc analyses designed to mitigate floor effects revealed substantial treatment effects for the experimental group regarding anxiety symptoms.”
- Also stated in: § Efficacy assessment · plain
“However, a significant difference in T1 between-groups anxiety symptoms [F(1,13) = 7.56, p = 0.017, ηp2 = 0.368] was found.”
- Also stated in: § Discussion · plain
“A significant difference between groups in anxiety symptoms was observed at post-treatment, with the EG reporting a larger reduction in symptoms than the CG.”
§ Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Efficacy assessment · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No significant differences were observed in clinical biomarkers from T0 to T3.”
- Also stated in: § Efficacy assessment · plain
“No significant differences were observed in serum CRP nor faecal calprotectin between T0 and T3 in either CG or EG (Supplementary Figures S4, S5).”
§ Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Efficacy assessment · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed no between-groups differences in symptoms at T1 after adjusting for T0 symptom scores for depression [F(1,13) = 3.613, p = 0.08, ηp2 = 0.217] or for stress [F(1,4) = 1.65, p = 0.268, ηp2 = 0.292].”
§ Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention > Results > Efficacy assessment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, there were no significant differences between groups concerning secondary outcomes (functional impairment, general and health-related quality of life, chronic illness-related shame, IBD symptoms, self-compassion, and psychological flexibility).”
§ Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
16 more claims
Create a free account to see all 48 claims and every source verdict.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 21
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- ConsistentF(1, 13) = 3.613reported p = .08 · recomputed p = .080
“F(1,13) = 3.613, p = .08”
- ConsistentF(1, 4) = 1.65reported p = .268 · recomputed p = .268
“F(1,4) = 1.65, p = .268”
- ConsistentF(1, 13) = 7.56reported p = .017 · recomputed p = .017
“F(1,13) = 7.56, p = .017”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention > Abstract > Methods
“Of the 355 patients screened, those who accepted to participate were randomly assigned to one of two conditions: experimental group (LIFEwithIBD; n = 25) or control group (waitlist; n = 29).”
§ Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention > Methods and materials > Participants
“A total of 76 participants were selected and randomly assigned to one of two conditions: the experimental group (EG; LIFEwithIBD + TAU: n = 38) or the control group (CG; TAU: n = 38) (Figure 1).”
Citations
Cites
(1995) · Cited by 6,909
Depression Anxiety Stress Scales
Lovibond, S. H., & Lovibond, P. F. (2011) · PsycTESTS Dataset · doi:10.1037/t01004-000 · Cited by 2,416
Prati, G., & Mancini, A. D. (2021) · Psychological Medicine · doi:10.1017/s0033291721000015 · Cited by 842 · cited 1×
“It is difficult to hypothesize their possible effects on this study, as studies show that the effects of lockdown periods on mental health are not the same for each individual (Prati and Mancini, 2021).”
BackgroundBarberio, B., Zamani, M., Black, C. J., Savarino, E. V., & Ford, A. C. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00014-5 · Cited by 758
Graham, C. D., Gouick, J., Krahé, C., & Gillanders, D. (2016) · Clinical Psychology Review · doi:10.1016/j.cpr.2016.04.009 · Cited by 476
Quality of life in inflammatory bowel disease: a systematic review and meta-analyses—part II
Knowles, S. R., Keefer, L., Wilding, H., Hewitt, C., Graff, L. A., & Mikocka-Walus, A. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy015 · Cited by 416
Halkjær, S. I., Christensen, A. H., Lo, B. Z. S., Browne, P. D., Günther, S., Hansen, L. H., & Petersen, A. M. (2018) · Gut · doi:10.1136/gutjnl-2018-316434 · Cited by 338
Wynne, B., McHugh, L., Gao, W., Keegan, D., Byrne, K., Rowan, C., Hartery, K., Kirschbaum, C., Doherty, G., Cullen, G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.030 · Cited by 188
Jedel, S., Hoffman, A., Merriman, P., Swanson, B., Voigt, R., Rajan, K. B., Shaikh, M., Li, H., & Keshavarzian, A. (2014) · Digestion · doi:10.1159/000356316 · Cited by 143
Gearing, R. E., Schwalbe, C. S. J., Lee, R., & Hoagwood, K. E. (2013) · Depression and Anxiety · doi:10.1002/da.22118 · Cited by 136 · cited 1×
“There is evidence that interventions with booster sessions provide better results at follow-up than those without sessions following the main interventional period (Gearing et al., 2013; Wesner et al., 2015).”
Background
Research works printed but not linked: 2
- Fox, 2012, Package ‘car’
- Palha, 2016, Perspetiva sobre a Saúde mental em Portugal: perspective on mental health in Portugal, Gazeta Médica
Cited by
Exploring the management and treatment of IBD from the perspective of psychological comorbidities
Feng, L., Cai, X., Zou, Q., Peng, Y., Xu, L., Wang, L., Liu, Q., & Lou, T. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241290685 · Cited by 15
Lin, K., Cavadino, A., Ow, M., Douglas, M., & Serlachius, A. S. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1587765 · Cited by 8
Kleiman, K., Marks, D. R., Block-Lerner, J., Tirch, D., Brady, V., Foote, B., & Silberstein-Tirch, L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1509396 · Cited by 4
Trindade, I. A., Soares, A. M., Skvarc, D., Carreiras, D., Pereira, J., Lourenço, Ó. D., Sampaio, F., de Sousa, B. C., Martins, T., Boaventura, P., et al. (2025) · Trials · doi:10.1186/s13063-024-08626-4 · Cited by 10
Self-citationHolistic care in inflammatory bowel disease: is it in REACH?
Said, H., Moulton, C. D., Hart, A. L., & Keefer, L. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf227 · Cited by 3
Metadata
- Authors
- Ferreira, C., Pereira, J., Skvarc, D., Oliveira, S., Galhardo, A., Ferreira, N. B., Lucena-Santos, P., Carvalho, S. A., Matos-Pina, I., Rocha, B. S., Portela, F., & Trindade, I. A.
- Affiliations
- University of Coimbra (PT)
- Örebro University (SE)
- Instituto Superior Miguel Torga (PT)
- University of Nicosia (CY)
- Centro de Neurociências e Biologia Celular (PT)
- Unidade Local de Saúde de Coimbra (PT)
- Corresponding author
- Ferreira, Cláudia
- Trindade, Inês A.
- ORCID
- Venue
- Frontiers in Psychology
- Publisher
- Frontiers Media SA
- Published
- 2024-05-09
- Volume
- 15
- Pages
- 1367913-1367913
- ISSN
- 1664-1078 (ISSN-L)
- PMC
- PMC11112702
- OpenAlex
- W4396771767
- Cited by
- 12
- References
- 36
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 1
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Mindfulness and Compassion Interventions
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- inflammatory bowel disease, acceptance and commitment therapy, compassion-focused therapy, group intervention, psychological distress, anxiety symptoms, stress symptoms, depression, treatment acceptability, inflammatory markers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention. https://app.cochat.ai/papers/10.3389/fpsyg.2024.1367913
- The paper
- Ferreira, C., Pereira, J., Skvarc, D., Oliveira, S., Galhardo, A., Ferreira, N. B., Lucena-Santos, P., Carvalho, S. A., Matos-Pina, I., Rocha, B. S., Portela, F., & Trindade, I. A. (2024). Randomized controlled trial of an Acceptance and Commitment Therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2024.1367913
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
